What peptide half-life means in a research context
Peptide half-life is the time it takes for a peptide's plasma concentration to fall by 50 percent after it enters circulation. Most peptides follow first-order elimination kinetics: the clearance rate is proportional to how much peptide is currently in the blood, so the half-life stays constant regardless of the starting dose. The StatPearls pharmacokinetics reference (NCBI Bookshelf) puts a number on this: after four to five half-lives, 94 to 97 percent of a compound following first-order kinetics has cleared the system.
That single number, half-life, is doing three jobs in a research protocol. It sets how often a compound needs to be dosed to hold plasma levels in a target range. It sets how long a washout period needs to run before a crossover study can start its second arm. And it sets the sampling schedule for any pharmacokinetic study, since blood draws timed too far apart will miss the concentration curve entirely.
Absorption: the injection route shapes the starting curve
For an injected peptide, half-life measurement starts the moment the compound leaves the injection site, not the moment the syringe empties. Subcutaneous and intramuscular routes produce different absorption curves because they deposit the peptide into tissue with different blood flow: intramuscular delivery reaches peak concentration faster, while subcutaneous delivery creates a depot effect that releases the peptide more slowly into the bloodstream.
That depot effect matters for how a half-life number gets interpreted. A peptide with a genuinely short intrinsic half-life can still show sustained plasma levels after subcutaneous injection, because absorption from the injection site is the rate-limiting step rather than clearance from the blood. Reading a pharmacokinetic study without checking the administration route is a common source of confusion when comparing half-life figures across papers.
Distribution: where the peptide goes and what it binds to
Once in circulation, an unmodified peptide typically has a small volume of distribution. Its size and charge keep it mostly in the plasma and extracellular fluid rather than partitioning into fat or binding extensively inside cells. This is different from small-molecule drugs, many of which distribute widely into tissue.
Plasma protein binding changes this picture substantially. A 2019 review in Drug Metabolism and Pharmacokinetics (Bumbaca, Li and Shah) catalogs how conjugation strategies extend circulation time: PEGylation of the antimicrobial peptide Bac7 stretched detectable plasma exposure out to 24 hours, an anti-TNF-alpha Fab fragment fused to a 40 kDa PEG chain reached a two-week half-life, and albumin conjugation took a single-chain antibody fragment from roughly 0.5 to 2 hours up to about 15 hours, a sevenfold increase. The same review notes that fusing GLP-1 to albumin extended its circulating duration from a couple of hours to six or seven days.
Semaglutide is the clinical example of that principle in production use. Its FDA label on DailyMed states the peptide is more than 99 percent bound to plasma albumin, with a terminal half-life of approximately one week. The label is explicit about the mechanism: albumin binding reduces renal clearance and shields the peptide backbone from proteolytic degradation, which is why a compound that would otherwise clear in hours instead needs once-weekly dosing. The semaglutide research overview covers the trial data behind this mechanism in more depth.
Clearance: why most unmodified peptides disappear fast
Two clearance routes dominate for peptides that are not chemically modified to resist them. The first is renal filtration. A 2026 review in Biophysica (Heaps et al.) puts the glomerular filtration cutoff at roughly 60 to 70 kDa; molecules smaller than that are filtered out of the blood by the kidney and are not efficiently reabsorbed.
Most research peptides, at a few hundred to a few thousand daltons, sit far under that threshold. The same review reports that free insulin-like growth factor I and II, both small peptide hormones, have circulating half-lives under 10 minutes once unbound from their carrier proteins, purely from glomerular filtration.
The second route is proteolytic degradation by plasma and tissue proteases, and this is where a peptide's own sequence matters. A 2021 paper in Clinical and Translational Science (Cavaco et al., 129 peptides across 51 sources) built a regression model linking serum half-life to specific sequence features: a higher share of nonpolar residues and the presence of two or more tyrosines were associated with longer half-life, while even one tryptophan residue or an isoelectric point of 10 or above shortened it. Across their validation set, measured half-lives ranged from 7.4 to 403.4 minutes, a fifty-fold spread driven almost entirely by sequence, not dose or route.
The scale of that variability shows up in PEPlife, a curated database published in Scientific Reports (Mathur et al., 2016) that logs 2,229 half-life measurements across 1,193 distinct peptides. The authors built it specifically because short half-life is one of the main obstacles to turning a promising peptide into a usable research tool or therapeutic candidate. BPC-157 is a working example: the first formal pharmacokinetic characterization found an elimination half-life under 30 minutes across all doses tested in rat and beagle dog models, regardless of injection route.
Practical implications for protocol design
A short intrinsic half-life pushes a protocol toward one of two designs: frequent dosing to maintain plasma levels, or a formulation change (conjugation, a slow-release vehicle) if sustained exposure is the actual research objective. Before assuming a compound needs multiple daily doses, check whether the published half-life reflects a bolus intravenous dose or a subcutaneous depot; the two numbers can differ by hours simply because of the absorption phase described above.
Washout periods for crossover designs should be sized off the longest half-life among the compounds being compared, not the shortest. Following the four-to-five-half-life rule from StatPearls, a peptide with a 30-minute half-life clears to background within two to three hours, while one bound tightly to albumin can take weeks. Running a fixed washout period across every arm of a study, rather than tailoring it to each compound, is a common design error that produces carryover confounds in the data.
For dose and concentration calculations that feed into a sampling schedule, the peptide dosing calculator handles the conversion from vial concentration to draw volume, which keeps the injected dose consistent across sampling timepoints. Studies run in a tropical research setting also need to confirm the reconstituted vial has not degraded between doses; the compound-specific handling notes outline expected potency windows for the peptides most commonly used in half-life and pharmacokinetic protocols.